KAREN KASCHAK: Open Payments
NPI 1013078906 · CAPE MAY COURT HOUSE, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,951 in 100 payments from 14 companies in 2025. Trend: 2023 $1,463 · 2024 $1,653 · 2025 $1,951
Food & beverage: $1,851Education: $100
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 18 | $372 |
| Alkermes, Inc. | 11 | $292 |
| Teva Pharmaceuticals USA, Inc. | 15 | $266 |
| Lundbeck LLC | 16 | $237 |
| E.R. Squibb & Sons, L.L.C. | 14 | $199 |
| Otsuka America Pharmaceutical, Inc. | 9 | $186 |
| ANI Pharmaceuticals, Inc. | 1 | $115 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $84 |
| Axsome Therapeutics, Inc. | 4 | $69 |
| Vanda Pharmaceuticals Inc. | 2 | $36 |
Products named: INGREZZA, REXULTI, COBENFY, AUSTEDO XR, ARISTADA, LYBALVI, PURIFIED CORTROPHIN GEL, CAPLYTA.
Industry payments across NJ — which companies pay providers there.
